PharmaEngine (ROCO:4162) Cyclically Adjusted FCF per Share: NT$3.93 (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4162 PharmaEngine Inc ROCO:4162
79 GF Score
Price NT$65.80
GF Value NT$115.94
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is PharmaEngine Cyclically Adjusted FCF per Share?

PharmaEngine ROCO:4162 -0.15% 79 Cyclically Adjusted FCF per Share is NT$3.93 as of Dec. 2025. GuruFocus rates ROCO:4162 with a GF Score™ of 79/100 and a GF Value™ of NT$115.94 (Significantly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

PharmaEngine's adjusted free cash flow per share for the three months ended in Dec. 2025 was NT$0.891. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is NT$3.93 for the trailing ten years ended in Dec. 2025.

During the past 12 months, PharmaEngine's average Cyclically Adjusted FCF Growth Rate was 29.70% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 17.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 15.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of PharmaEngine was 17.20% per year. The lowest was 10.60% per year. And the median was 15.80% per year.

As of today (2026-07-27), PharmaEngine's current stock price is NT$65.80. PharmaEngine's Cyclically Adjusted FCF per Share for the quarter that ended in Dec. 2025 was NT$3.93. PharmaEngine's Cyclically Adjusted Price-to-FCF of today is 16.74.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of PharmaEngine was 59.52. The lowest was 13.64. And the median was 32.10.


PharmaEngine  (ROCO:4162) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

PharmaEngine's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=65.80/3.93
=16.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of PharmaEngine was 59.52. The lowest was 13.64. And the median was 32.10.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


PharmaEngine Cyclically Adjusted FCF per Share Related Terms


PharmaEngine Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for PharmaEngine's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaEngine Cyclically Adjusted FCF per Share Chart

PharmaEngine Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.24 2.44 2.75 3.03 3.93

PharmaEngine Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.03 4.36 4.09 3.82 3.93

ROCO:4162 vs VRTX, REGN, RVMD: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, PharmaEngine's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmaEngine Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaEngine's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where PharmaEngine's Cyclically Adjusted Price-to-FCF falls into.


ROCO:4162
79GF Score
PharmaEngine Inc ROCO:4162
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaEngine Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PharmaEngine's adjusted Free Cash Flow per Share data for the three months ended in Dec. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Dec. 2025 (Change)*Current CPI (Dec. 2025)
=0.891/324.0540*324.0540
=0.891

Current CPI (Dec. 2025) = 324.0540.

PharmaEngine Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201603 -0.393 238.132 -0.535
201606 2.000 241.018 2.689
201609 -0.669 241.428 -0.898
201612 5.277 241.432 7.083
201703 -1.115 243.801 -1.482
201706 -0.753 244.955 -0.996
201709 -0.222 246.819 -0.291
201712 -0.166 246.524 -0.218
201803 4.566 249.554 5.929
201806 -0.267 251.989 -0.343
201809 0.448 252.439 0.575
201812 0.312 251.233 0.402
201903 0.149 254.202 0.190
201906 0.133 256.143 0.168
201909 0.235 256.759 0.297
201912 -0.408 256.974 -0.515
202003 0.298 258.115 0.374
202006 0.033 257.797 0.041
202009 0.136 260.280 0.169
202012 -0.018 260.474 -0.022
202103 4.747 264.877 5.808
202106 0.848 271.696 1.011
202109 0.118 274.310 0.139
202112 0.679 278.802 0.789
202203 0.444 287.504 0.500
202206 0.270 296.311 0.295
202209 0.442 296.808 0.483
202212 0.250 296.797 0.273
202303 0.629 301.836 0.675
202306 0.670 305.109 0.712
202309 -0.037 307.789 -0.039
202312 0.523 306.746 0.553
202403 0.582 312.332 0.604
202406 1.210 314.175 1.248
202409 0.539 315.301 0.554
202412 0.838 315.605 0.860
202503 12.573 319.799 12.740
202506 -1.777 322.561 -1.785
202509 0.369 324.800 0.368
202512 0.891 324.054 0.891

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of NT$3.93 mean?
PharmaEngine (ROCO:4162) has a Cyclically Adjusted FCF per Share of NT$3.93 as of Dec. 2025. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PharmaEngine and its competitors.
Is PharmaEngine's Cyclically Adjusted FCF per Share too high?
PharmaEngine's current Cyclically Adjusted FCF per Share is NT$3.93. Overall, PharmaEngine has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PharmaEngine's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
PharmaEngine's Cyclically Adjusted FCF per Share of NT$3.93 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on PharmaEngine and its competitors. PharmaEngine's current Cyclically Adjusted FCF per Share is NT$3.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaEngine stock overvalued right now?
Based on GuruFocus' analysis, PharmaEngine (ROCO:4162) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$115.94, compared to a current price of NT$65.80 — trading 43.2% below its estimated fair value. The current Cyclically Adjusted FCF per Share is NT$3.93. PharmaEngine's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For PharmaEngine (ROCO:4162), the current Cyclically Adjusted FCF per Share is NT$3.93 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PharmaEngine (ROCO:4162) Overvalued in 2026?

Based on GuruFocus' analysis, PharmaEngine stock appears to be undervalued. The current stock price of NT$65.80 is trading 43.2% below its estimated GF Value™ of NT$115.94. GuruFocus considers PharmaEngine to be Significantly Undervalued.

Key valuation signals for ROCO:4162:

  • Cyclically Adjusted FCF per Share: NT$3.93
  • GF Value™: NT$115.94 vs. price of NT$65.80 (43.2% below fair value)
  • GF Score™: 79/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4162 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


PharmaEngine Business Description

Address No. 10, Minsheng East Road, 11th Floor, Section 3, Taipei, TWN, 104
PharmaEngine Inc is a biopharmaceutical company engaged in the development of new drugs and therapeutic drugs for cancer. It is a specialty pharma company that adopts the no research, development-only model and the networked pharma model for new drug development. Its key products and pipeline projects include ONIVYDE, a treatment for metastatic pancreatic cancer approved in multiple markets, as well as oncology candidates such as PEP07 and PEP08. It generates revenue from the sales of goods.
79GF Score

Get the complete analysis for ROCO:4162

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$65.80
Price
NT$115.94
GF Value